同步放化疗与序贯放化疗治疗中晚期非小细胞肺癌的疗效及对不良反应率的影响  

Effect of Synchronous chemoradiotherapy and sequential chemoradiotherapy in treating advanced non-small cell lung cancer and the effect of the adverse reaction rate

作　　者：钱昊初 QIAN Haochu(Department of Medical Oncology,Anshan Cancer Hospital,Anshan,Liaoning,114000,China)

机构地区：[1]鞍山市肿瘤医院肿瘤内科,辽宁鞍山114000

出　　处：《当代医学》2022年第29期180-182,共3页Contemporary Medicine

摘　　要：目的探讨同步放化疗于序贯放化疗治疗中晚期非小细胞肺癌的疗效及对不良反应率的影响。方法选取2019年1月至2021年5月本院收治的92例中晚期非小细胞肺癌作为研究对象,按照随机数字表格法分为对照组和实验组,每组46例。对照组采用序贯放化疗治疗,实验组采用同步放化疗治疗,比较两组临床指标[血管内皮生长因子(VEGF)、生存率]、临床疗效及不良反应(胃肠道反应、白细胞下降、放射性损伤)发生情况。结果治疗后,实验组VEGF低于对照组,实验组生存率高于对照组(P<0.05);实验组治疗总有效率为73.91%,高于对照组的52.17%(P<0.05);实验组不良反应发生率为15.22%,低于对照组的34.78%(P<0.05)。结论同步放化疗治疗中晚期非小细胞肺癌患者效果确切,能降低血管内皮生长因子,减少胃肠道反应、白细胞下降、放射性损伤等不良反应发生率,提高患者生存率,值得临床推广应用。Objective To investigate the curative effect of synchronous chemoradiotherapy and its effect on the adverse reaction rate in treating advanced non-small cell lung cancer.Methods 92 cases of advanced non-small cell lung cancer treated from January 2019 to May 2021 were selected as research subjects,and they were divided into control group and experimental group according to random number table method,with 46 cases in each group.The control group was treated with sequential chemoradiotherapy,and the experimental group used concurrent chemoradiotherapy,the clinical indicators(vascular endothelial growth factor[VEGF],survival rate),clinical efficacy and adverse effects(gastrointestinal reaction,leukocyte decline,radioactive damage)were compared between the two groups.Results After treatment,VEGF in the experimental group was lower than that in the control group,and the survival rate in the experimental group was higher than that in the control group(P<0.05).The total effective rate of the experimental group was 73.91%,which was higher than 52.17%of the control group(P<0.05).The incidence of adverse reactions in the experimental group was 15.22%,lower than 34.78%in the control group(P<0.05).Conclusion Synchronous chemoradiotherapy in the treatment of patients with advanced non-small cell lung cancer is effective,can reduce vascular endothelial growth factor,reduce the incidence of gastrointestinal reactions,leukopenia,radiation damage and other adverse reactions,improve the survival rate of patients,worthy of clinical promotion and application.

关 键 词：中晚期非小细胞肺癌 临床疗效 不良反应 同步放化疗 序贯放化疗 

分 类 号：R734.2[医药卫生—肿瘤]